Health condition
Tuberous sclerosis in adults
Tuberous sclerosis complex (TSC) causes benign growths in brain, kidneys, skin, lungs and heart - adult care revolves around kidney surveillance, lung disease in women, epilepsy management and mTOR inhibitor therapy where indicated.
Why trust this guide
- 01
Editorial team
Written by our editorial team from the UK sources listed on each page.
- 02
Sourced from guidance
Checked against current NHS and UK specialist society guidance at the time of review.
- 03
Current for 2026
Reviewed on 2026-09-27 with the next review scheduled for 2027-09-27.
Key facts
The essentials at a glance.
Which gene and test confirm it, who should be tested in the family, and which specialist to see.
-
Caused by TSC1 or TSC2 variants; autosomal dominant - two-thirds are new mutations; TSC2 tends to run more severely
-
The central adult risk is renal angiomyolipomas, which can bleed when large - kidney MRI every 1-3 years is standard
-
Women with TSC should be assessed for lymphangioleiomyomatosis (LAM) with chest CT and lung function
-
mTOR inhibitors (everolimus, sirolimus) shrink angiomyolipomas and treat LAM and refractory epilepsy - a genuine change in the treatment landscape
Understanding the condition
What it is and what happens next.
What causes it, how it is confirmed, and the testing and specialist routes available in the UK.
What it is and how it presents
TSC in adulthood is a different condition from TSC in childhood: seizures and developmental concerns dominate early, while kidneys and lungs claim priority later. Angiomyolipomas grow silently until one exceeds the size at which spontaneous bleeding becomes a real risk - the rationale for regular MRI and for treating proactively with mTOR inhibitors rather than waiting for emergencies. Skin findings, dental pits and behavioural or psychiatric aspects (TAND) also deserve routine attention rather than ad hoc responses.
Testing, surveillance and specialist care
Adults do best under a coordinated TSC service - or a nephrology-genetics partnership using the international surveillance guidelines - with kidney imaging on schedule, LAM screening for women, epilepsy review and access to everolimus when lesions grow. Genetic testing confirms the variant, supports family cascade testing and underpins reproductive counselling. NHS clinical genetics services carry some of the longest waits in the health service, often many months for a first appointment, whereas private genetic testing and a specialist review can typically be arranged within around two weeks.
Seeing a specialist
Who to see, and how quickly you can be seen.
The specialist for this condition is usually a specialist TSC clinic (genetics, nephrology and neurology input). Your GP can refer you on the NHS, or you can arrange a private consultation directly.
A quiet reminder
This guide is for information, not medical advice.
Your GP knows your history and can tell you which parts apply to you. If in doubt, see them - and seek urgent care for any emergency symptoms.
Frequently asked
Common questions about Tuberous sclerosis in adults.
Quick, plain-English answers to what people ask us most.
-
What is tuberous sclerosis in adults?
Tuberous sclerosis complex is a genetic condition causing benign tumours (growths) to form in multiple organs including the brain, kidneys, skin, heart and lungs; adults with the condition need ongoing surveillance for these tumours.
-
What causes tuberous sclerosis?
It is caused by a mutation in one of two genes, TSC1 or TSC2, which normally help regulate cell growth; the mutation can be inherited from a parent or, in about two-thirds of cases, occur newly (spontaneously) in the affected individual.
-
What are the symptoms in adults?
Presentation varies widely and can include skin changes (such as facial angiofibromas), seizures or a history of seizures, kidney growths (angiomyolipomas), lung involvement (particularly in women, called LAM), and, in some, learning or mental health difficulties.
-
Is tuberous sclerosis dangerous?
Severity varies enormously; some adults have mild disease with minimal impact, while others face significant complications from kidney tumours, lung disease, or seizures, so regular specialist surveillance is important to catch and manage problems early.
-
Is tuberous sclerosis hereditary?
Yes, it's inherited in an autosomal dominant pattern when passed from an affected parent, giving each child a 50% chance of inheriting it, though many cases arise from a new mutation with no family history.
-
Can tuberous sclerosis be cured?
There's no cure, but with the discovery that TSC affects a specific cell growth pathway (mTOR), targeted medications (mTOR inhibitors) can shrink certain tumours and reduce seizure frequency, alongside surgery or other treatments as needed for specific complications.
-
How is tuberous sclerosis managed in adults?
Management involves regular surveillance imaging of the kidneys and brain, monitoring for lung disease, skin treatment for cosmetic lesions, and mTOR inhibitor medication or other targeted treatment for significant tumours or seizures.
-
How often should surveillance happen?
Surveillance schedules vary by organ system but typically involve periodic MRI of the brain and kidneys and, in women, monitoring for lung involvement, usually reviewed with a specialist multidisciplinary team every one to three years or as clinically indicated.
-
Tuberous sclerosis vs neurofibromatosis - what's the difference?
Both are genetic conditions causing benign tumours in multiple organs, but they involve different genes and have distinct patterns of skin findings, tumour types, and organ involvement, requiring different surveillance protocols.
-
When should I see a specialist, and how quickly can I be seen privately?
Ongoing specialist follow-up is recommended for anyone with tuberous sclerosis. NHS specialist genetics or neurology clinics can have lengthy waits; private specialists experienced in TSC can often see you within about two weeks.